查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701666

全球家庭檢測 (LDT) 市場：產業分析、規模、佔有率、成長、趨勢和預測（2025-2032 年）

Laboratory Developed Test Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 319 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

主要發現

  • 家庭自控測試（LDT）市場規模：90億美元（2025年）
  • 預計市場價值：139億美元（2032年）
  • 全球市場成長率：6.4%（2025年至2032年的複合年成長率）

上門檢測（LDT）市場 - 報告範圍

家庭準備測試（LDT）市場包括在單一實驗室內設計、製造和使用的診斷測試。當不存在商業性可用的替代品時，這些測試尤其重要，為獨特的患者群體和新出現的健康威脅提供量身定做的解決方案。 LDT廣泛應用於腫瘤學、遺傳學、感染疾病、罕見疾病等專科診斷領域。個人化醫療需求的不斷成長、慢性病和感染疾病的流行以及分子診斷技術的進步是推動市場成長的主要因素。

市場成長動力

多種因素推動了全球送貨上門檢測 (LDT) 市場的成長。個人化醫療的快速發展和客製化診斷解決方案的需求正在推動 LDT 的採用。技術進步，特別是分子診斷和次世代定序的技術進步，顯著提高了這些測試的速度、準確性和可靠性。此外，全球癌症、遺傳疾病和感染疾病負擔的不斷加重也增加了對專業化和彈性診斷方案的需求。 COVID-19 疫情進一步凸顯了快速、適應性診斷工具的重要性，並提高了人們對 LDT 的認知和監管支持。診斷研究的投資不斷增加，以及學術實驗室在開發新型檢測方法方面發揮的日益重要的作用，也有助於推動市場向前發展。

市場限制

儘管送貨上門檢測 (LDT) 市場具有諸多優勢，但它也面臨一些挑戰。一個主要問題是各地區缺乏統一的法律規範，這可能導致測試品質和病人安全的差異。即將訂定的監管變化，特別是美國提案的《VALID法案》下的變化，可能會給實驗室帶來更大的合規負擔，增加營運成本並限制創新。此外，LDT 通常需要大量的專業知識和基礎設施，這限制了其廣泛應用，尤其是在資源匱乏的環境中。對可重複性、驗證和標準化的擔憂進一步阻礙了其廣泛採用。最後，來自 FDA核准的商業測試的競爭可能會減少 LDT 在某些應用中的市場佔有率。

市場機會

由於診斷技術的不斷創新和精準醫療的擴展，LDT 市場提供了巨大的成長機會。人工智慧和生物資訊學日益融入臨床測試，為開發更準確、更有效率的測試提供了新的可能性。醫療基礎設施和診斷能力的改善，特別是在亞太地區和拉丁美洲等新興經濟體，為 LDT 的採用鋪平了新的道路。此外，隨著對早期疾病檢測和標靶治療的需求不斷成長，LDT 在罕見疾病和藥物基因組學等利基診斷領域具有發揮核心作用的優勢。此外，學術研究中心和商業診斷公司之間的合作可能會加速 LDT 的發展和市場覆蓋。

本報告研究了全球送貨上門測試 (LDT) 市場，並對市場動態進行了詳細分析，包括成長動力、趨勢、機會和挑戰。

目錄

第1章執行摘要

第2章 市場概述

  • 市場範圍和定義
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
    • 主要趨勢
  • 宏觀經濟因素
    • 全球產業展望
    • 全球GDP成長前景
  • COVID-19影響分析
  • 預測因子－相關性和影響力

第3章 增值考慮

  • 產品採用分析
  • 監管格局
  • 贖回方案
  • PESTLE分析
  • 主要企業促銷策略

第4章 全球家庭考試（LDT）展望

  • 主要亮點
    • 市場規模及與前一年同期比較
    • 絕對的商機
  • 市場規模分析及預測
    • 市場規模表現分析（2019-2024）
    • 當前市場規模分析與預測（2025-2032）
  • 全球家庭考試（LDT）展望：考試類型
    • 簡介/主要發現
    • 按測試類型分類的市場規模績效分析（2019-2024）
    • 按測試類型分類的當前市場規模分析和預測（2025-2032）
    • 市場吸引力分析：測試類型
  • 全球家庭考試 (LDT) 展望：應用
    • 簡介/主要發現
    • 按應用分類的市場規模表現（2019-2024）
    • 目前市場規模分析及應用預測（2025-2032）
    • 市場吸引力分析：應用
  • 全球家庭考試 (LDT) 展望：最終用戶
    • 簡介/主要發現
    • 最終用戶的市場規模表現（2019-2024）
    • 目前市場規模分析及最終用戶預測（2025-2032）
    • 市場吸引力分析：最終用戶

5. 全球家庭考試（LDT）展望－地區

  • 主要亮點
  • 市場規模績效分析：按地區（2019-2024）
  • 目前市場規模分析及各地區預測（2025-2032）
    • 北美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：地區

6. 北美家庭考試（LDT）展望

7. 歐洲家庭考試（LDT）展望

第8章 東亞家庭考試（LDT）展望

9. 南亞和大洋洲家庭考試（LDT）展望

10. 拉丁美洲住宿測試（LDT）展望

11. 中東和非洲家庭考試（LDT）展望

第12章競爭格局

  • 市場佔有率分析（2025年）
  • 市場結構
    • 競爭強度圖：按市場
    • 競爭儀錶板
  • 公司簡介（詳情－概述、財務狀況、策略、最新發展）
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Kaneka Eurogentec SA
    • Vastian
    • Roche Diagnostics
    • Adaptive Biotechnologies.
    • Guardant Health, Inc.
    • Smiths Medical
    • Quest Diagnostics
    • Beckman Coulter
    • OPKO Health, Inc.
    • Siemens Medical Solutions USA, Inc.
    • Quanterix
    • Proteomics International

第13章 附錄

簡介目錄
Product Code: PMRREP3430

Persistence Market Research has recently released a comprehensive report on the global Laboratory Developed Test (LDT) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Laboratory Developed Test Market Size (2025E): US$ 9.0 Bn
  • Projected Market Value (2032F): US$ 13.9 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.4%

Laboratory Developed Test Market - Report Scope:

The Laboratory Developed Test (LDT) market encompasses diagnostic tests that are designed, manufactured, and used within a single laboratory. These tests are particularly vital when no commercially available alternatives exist, providing solutions tailored for unique patient populations or emerging health threats. LDTs are widely used in specialized diagnostic areas such as oncology, genetics, infectious diseases, and rare disorders. The increasing demand for personalized medicine, rising prevalence of chronic and infectious diseases, and technological advancements in molecular diagnostics are key contributors to market growth.

Market Growth Drivers:

Several key factors are fueling the growth of the global Laboratory Developed Test market. The rapid rise in personalized medicine and the need for customized diagnostic solutions are encouraging the use of LDTs. Technological advancements, especially in molecular diagnostics and next-generation sequencing, have significantly improved the speed, accuracy, and reliability of these tests. Moreover, the growing burden of cancer, genetic disorders, and infectious diseases globally has amplified the demand for specialized and flexible diagnostic options. The COVID-19 pandemic further highlighted the importance of rapid and adaptable diagnostic tools, driving both awareness and regulatory support for LDTs. Increasing investments in diagnostic research and the growing role of academic and research institutions in developing novel assays also propel the market forward.

Market Restraints:

Despite their advantages, the Laboratory Developed Test market faces several challenges. A key concern is the lack of uniform regulatory oversight across regions, which can lead to variability in test quality and patient safety. The upcoming regulatory changes, particularly in the United States under the proposed VALID Act, could impose stricter compliance burdens on labs, increasing operational costs and limiting innovation. In addition, LDTs often require significant expertise and infrastructure, restricting their widespread use, especially in low-resource settings. Concerns around reproducibility, validation, and standardization further hinder broader adoption. Lastly, competition from FDA-approved commercial tests can reduce the market share for LDTs in certain applications.

Market Opportunities:

The LDT market offers substantial growth opportunities driven by continued innovation in diagnostics and the expanding scope of precision medicine. The increasing integration of artificial intelligence and bioinformatics into laboratory testing presents new possibilities for more accurate and efficient test development. Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing improved healthcare infrastructure and diagnostic capabilities, opening up new avenues for LDT adoption. Moreover, as demand grows for early disease detection and targeted therapies, LDTs are well-positioned to play a central role in niche diagnostic areas such as rare diseases and pharmacogenomics. Partnerships between academic research centers and commercial diagnostic companies can also accelerate LDT development and market reach.

Key Questions Answered in the Report:

  • What are the primary factors driving the global Laboratory Developed Test market's growth?
  • Which regions and application areas are experiencing the highest demand for LDTs?
  • How are technological innovations in molecular diagnostics shaping the LDT landscape?
  • Who are the key players in the Laboratory Developed Test market, and what strategies are they adopting to remain competitive?
  • What are the regulatory developments and future projections for the global LDT market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Laboratory Developed Test market, such as Thermo Fisher Scientific Inc., QIAGEN, Roche Diagnostics, and Quest Diagnostics, are focusing on expanding their test portfolios, particularly in oncology, infectious diseases, and genetic testing. These companies are leveraging strategic collaborations with academic institutions, biotech firms, and healthcare providers to enhance innovation and accelerate time-to-market for novel assays. Investment in automation, AI-based data analysis tools, and next-generation sequencing technologies is enabling improved test accuracy and throughput. Furthermore, companies are engaging with regulatory bodies to ensure compliance and support smoother transitions under evolving LDT regulations.

Companies Covered in This Report:

  • Thermo Fisher Scientific Inc.
  • Kaneka Eurogentec S.A.
  • QIAGEN
  • Vastian
  • Roche Diagnostics
  • Adaptive Biotechnologies
  • Guardant Health, Inc.
  • Smiths Medical
  • Quest Diagnostics
  • Beckman Coulter
  • OPKO Health, Inc.

Laboratory Developed Test Market Segmentation:

By Test Type:

  • Clinical Biochemistry
  • Haematology
  • Immunology
  • Microbiology
  • Molecular Diagnostics
  • Others

By Application:

  • Oncology
  • Genetics
  • Infectious Diseases
  • Autoimmune Disorders
  • Others

By End User:

  • Hospital Laboratories
  • Specialty Diagnostics Centers
  • Clinical Research Organizations
  • Research Institutes
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Laboratory Developed Test Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Reimbursement Scenario
  • 3.4. PESTLE Analysis
  • 3.5. Promotional Strategies, By Key Players

4. Global Laboratory Developed Test Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Laboratory Developed Test Outlook: Test Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
      • 4.3.3.1. Clinical Biochemistry
      • 4.3.3.2. Hematology
      • 4.3.3.3. Immunology
      • 4.3.3.4. Microbiology
      • 4.3.3.5. Molecular Diagnostics
      • 4.3.3.6. Others
    • 4.3.4. Market Attractiveness Analysis: Test Type
  • 4.4. Global Laboratory Developed Test Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn), By Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.4.3.1. Oncology
      • 4.4.3.2. Genetics
      • 4.4.3.3. Infectious Diseases
      • 4.4.3.4. Autoimmune Disorders
      • 4.4.3.5. Other Conditions
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Laboratory Developed Test Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn), By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospital Laboratories
      • 4.5.3.2. Specialty Diagnostics Centers
      • 4.5.3.3. Clinical Research Organizations
      • 4.5.3.4. Research Institutes
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Laboratory Developed Test Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Laboratory Developed Test Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Test Type
    • 6.2.3. By Application
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 6.4.1. Clinical Biochemistry
    • 6.4.2. Hematology
    • 6.4.3. Immunology
    • 6.4.4. Microbiology
    • 6.4.5. Molecular Diagnostics
    • 6.4.6. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.5.1. Oncology
    • 6.5.2. Genetics
    • 6.5.3. Infectious Diseases
    • 6.5.4. Autoimmune Disorders
    • 6.5.5. Other Conditions
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospital Laboratories
    • 6.6.2. Specialty Diagnostics Centers
    • 6.6.3. Clinical Research Organizations
    • 6.6.4. Research Institutes
    • 6.6.5. Others
  • 6.7. Market Attractiveness Analysis

7. Europe Laboratory Developed Test Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Test Type
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 7.4.1. Clinical Biochemistry
    • 7.4.2. Hematology
    • 7.4.3. Immunology
    • 7.4.4. Microbiology
    • 7.4.5. Molecular Diagnostics
    • 7.4.6. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.5.1. Oncology
    • 7.5.2. Genetics
    • 7.5.3. Infectious Diseases
    • 7.5.4. Autoimmune Disorders
    • 7.5.5. Other Conditions
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospital Laboratories
    • 7.6.2. Specialty Diagnostics Centers
    • 7.6.3. Clinical Research Organizations
    • 7.6.4. Research Institutes
    • 7.6.5. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia Laboratory Developed Test Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Test Type
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 8.4.1. Clinical Biochemistry
    • 8.4.2. Hematology
    • 8.4.3. Immunology
    • 8.4.4. Microbiology
    • 8.4.5. Molecular Diagnostics
    • 8.4.6. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.5.1. Oncology
    • 8.5.2. Genetics
    • 8.5.3. Infectious Diseases
    • 8.5.4. Autoimmune Disorders
    • 8.5.5. Other Conditions
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospital Laboratories
    • 8.6.2. Specialty Diagnostics Centers
    • 8.6.3. Clinical Research Organizations
    • 8.6.4. Research Institutes
    • 8.6.5. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Laboratory Developed Test Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Test Type
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 9.4.1. Clinical Biochemistry
    • 9.4.2. Hematology
    • 9.4.3. Immunology
    • 9.4.4. Microbiology
    • 9.4.5. Molecular Diagnostics
    • 9.4.6. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.5.1. Oncology
    • 9.5.2. Genetics
    • 9.5.3. Infectious Diseases
    • 9.5.4. Autoimmune Disorders
    • 9.5.5. Other Conditions
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospital Laboratories
    • 9.6.2. Specialty Diagnostics Centers
    • 9.6.3. Clinical Research Organizations
    • 9.6.4. Research Institutes
    • 9.6.5. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America Laboratory Developed Test Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Test Type
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 10.4.1. Clinical Biochemistry
    • 10.4.2. Hematology
    • 10.4.3. Immunology
    • 10.4.4. Microbiology
    • 10.4.5. Molecular Diagnostics
    • 10.4.6. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.5.1. Oncology
    • 10.5.2. Genetics
    • 10.5.3. Infectious Diseases
    • 10.5.4. Autoimmune Disorders
    • 10.5.5. Other Conditions
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospital Laboratories
    • 10.6.2. Specialty Diagnostics Centers
    • 10.6.3. Clinical Research Organizations
    • 10.6.4. Research Institutes
    • 10.6.5. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Laboratory Developed Test Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Test Type
    • 11.2.3. By Application
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 11.4.1. Clinical Biochemistry
    • 11.4.2. Hematology
    • 11.4.3. Immunology
    • 11.4.4. Microbiology
    • 11.4.5. Molecular Diagnostics
    • 11.4.6. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.5.1. Oncology
    • 11.5.2. Genetics
    • 11.5.3. Infectious Diseases
    • 11.5.4. Autoimmune Disorders
    • 11.5.5. Other Conditions
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospital Laboratories
    • 11.6.2. Specialty Diagnostics Centers
    • 11.6.3. Clinical Research Organizations
    • 11.6.4. Research Institutes
    • 11.6.5. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Test Types
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Thermo Fisher Scientific Inc.
      • 12.3.2.1. Overview
      • 12.3.2.2. Segments and Test Types
      • 12.3.2.3. Key Financials
      • 12.3.2.4. Market Developments
      • 12.3.2.5. Market Strategy
    • 12.3.3. Kaneka Eurogentec S.A.
      • 12.3.3.1. Overview
      • 12.3.3.2. Segments and Test Types
      • 12.3.3.3. Key Financials
      • 12.3.3.4. Market Developments
      • 12.3.3.5. Market Strategy
    • 12.3.4. Vastian
      • 12.3.4.1. Overview
      • 12.3.4.2. Segments and Test Types
      • 12.3.4.3. Key Financials
      • 12.3.4.4. Market Developments
      • 12.3.4.5. Market Strategy
    • 12.3.5. Roche Diagnostics
      • 12.3.5.1. Overview
      • 12.3.5.2. Segments and Test Types
      • 12.3.5.3. Key Financials
      • 12.3.5.4. Market Developments
      • 12.3.5.5. Market Strategy
    • 12.3.6. Adaptive Biotechnologies.
      • 12.3.6.1. Overview
      • 12.3.6.2. Segments and Test Types
      • 12.3.6.3. Key Financials
      • 12.3.6.4. Market Developments
      • 12.3.6.5. Market Strategy
    • 12.3.7. Guardant Health, Inc.
      • 12.3.7.1. Overview
      • 12.3.7.2. Segments and Test Types
      • 12.3.7.3. Key Financials
      • 12.3.7.4. Market Developments
      • 12.3.7.5. Market Strategy
    • 12.3.8. Smiths Medical
      • 12.3.8.1. Overview
      • 12.3.8.2. Segments and Test Types
      • 12.3.8.3. Key Financials
      • 12.3.8.4. Market Developments
      • 12.3.8.5. Market Strategy
    • 12.3.9. Quest Diagnostics
      • 12.3.9.1. Overview
      • 12.3.9.2. Segments and Test Types
      • 12.3.9.3. Key Financials
      • 12.3.9.4. Market Developments
      • 12.3.9.5. Market Strategy
    • 12.3.10. Beckman Coulter
      • 12.3.10.1. Overview
      • 12.3.10.2. Segments and Test Types
      • 12.3.10.3. Key Financials
      • 12.3.10.4. Market Developments
      • 12.3.10.5. Market Strategy
    • 12.3.11. OPKO Health, Inc.
      • 12.3.11.1. Overview
      • 12.3.11.2. Segments and Test Types
      • 12.3.11.3. Key Financials
      • 12.3.11.4. Market Developments
      • 12.3.11.5. Market Strategy
    • 12.3.12. Siemens Medical Solutions USA, Inc.
      • 12.3.12.1. Overview
      • 12.3.12.2. Segments and Test Types
      • 12.3.12.3. Key Financials
      • 12.3.12.4. Market Developments
      • 12.3.12.5. Market Strategy
    • 12.3.13. Quanterix
      • 12.3.13.1. Overview
      • 12.3.13.2. Segments and Test Types
      • 12.3.13.3. Key Financials
      • 12.3.13.4. Market Developments
      • 12.3.13.5. Market Strategy
    • 12.3.14. Proteomics International
      • 12.3.14.1. Overview
      • 12.3.14.2. Segments and Test Types
      • 12.3.14.3. Key Financials
      • 12.3.14.4. Market Developments
      • 12.3.14.5. Market Strategy

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations